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Abstract: The worldwide emergence of multidrug-resistant human immunodeficiency virus 
(HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the 
past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside 
reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available 
for treatment. It is important to assess how these new ARVs might be most judiciously used, 
paying close attention to viral susceptibility patterns, pharmacodynamic   parameters, and the 
likelihood that patients will adhere to their therapy. Herein we review published material in 
Medline, EMBASE, and ISI for each antiretroviral agent/classes   currently approved and sum-
marize the available data on their efficacy, safety, and pharmacologic parameters. We focus on 
the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, 
adolescents, and adults with a history of multidrug-resistant HIV .
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Introduction
One in 155 adults and adolescents are infected with human immunodeficiency virus 
(HIV) globally, with an astonishing rate of one in 21 in Sub-Saharan Africa.1 In the 
US alone, more than half a million people were living with HIV in 2007, and 44,000 
new cases were reported in the same year.2 Although safe and effective antiretroviral 
(ARV) treatment is now available, the prevalence of genotypic resistance to protease 
inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) has 
steadily increased.3 In treatment-naïve adolescents, genotypic resistance has been 
reported to be as high as 15%.4 Given this scenario it is now more important than 
ever to understand how newer ARV agents may provide therapeutic alternatives for 
treatment-naïve and treatment-experienced HIV-infected patients.
The appearance of HIV-resistant strains for the most part is due to the develop-
ment of point mutations in the HIV genome. Because HIV reverse transcriptase lacks 
the proofreading abilities of human DNA polymerase, 0.2 to 1 new point mutations 
may appear during each viral replication cycle.5 This translates into approximately 
10,000 new mutations per day. Fortunately for the host, most of these mutations are 
lethal to the virus and thus do not result in added ARV resistance.5 Resistance only 
occurs when the mutation induces conformational changes which allow the virus 
to overcome the action of the inhibiting agent, while maintaining the activity of the 
enzyme. When HIV does develop a beneficial point mutation, the corresponding genetic 
sequence is amplified by selective pressures of ARV therapy. These genetic changes in 
the viral genome and their effects are also the basis for available resistance testing.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Resistance testing
Resistance testing helps to direct therapy by avoiding the 
use of ineffective or inappropriate ARV therapy. For this 
reason the current adult and adolescent HIV-1 guidelines 
recommend resistance testing for all new patients entering 
into care, HIV-positive women who are pregnant or plan-
ning to become pregnant, and when considering changes 
to a patient’s ARV regimen due to suboptimal viral load 
reduction or virologic failure.6 The pediatric HIV guidelines 
also recommend resistance testing prior to starting therapy 
in treatment-naïve children, for treatment failure, and when 
considering the start of a CCR5 antagonist.7
HIV-resistance patterns can be assessed by using either 
a genotypic assay or by determining its phenotypic suscep-
tibility to ARVs. Genotypic assays screen viral genes for 
mutations which confer resistance to specific ARVs or entire 
classes of agents. This is done by either genomic mapping 
or the use of a DNA probe.6 The resulting list of mutations 
is interpreted using a regularly updated database containing 
mutations known to confer ARV resistance.8 Phenotypic 
testing involves the use of different concentrations of spe-
cific ARVs against the virus in vivo.6 Results of this test 
indicate the concentration at which 50% of the HIV viral 
replication is inhibited in culture (IC50).6 A combination of 
phenotypic and genotypic tests, known as virtual phenotyp-
ing, has also been used.9 This method involves the use of 
a database, which matches a genotypic pattern to a known 
phenotypic profile.9
Rates of virologic success, defined as achieving a viral 
load of ,200 copies/mL of blood, where compared between 
patients randomized to ARV therapy directed by genotyp-
ing, phenotyping, or standard of care (NARVAL trial).10,11 
Patients allocated to therapy chosen by genotypic analysis 
(44/183) trended toward increased virologic success when 
compared with those whose therapy was chosen by phe-
notyping (36/183; P = 0.068) or standard of care (36/152; 
P = 0.052).10 Using multivariate analysis, patients in the 
genotypic regimen arm were found to have a higher likeli-
hood of achieving virologic success than patients receiving 
standard of care (odds ratio [OR] 2.13 (95% confidence 
interval [CI] 1.20–3.79; P = 0.01)].11 In another study, ARV 
treatment was chosen according to virtual phenotype and 
then compared with treatment chosen based on genotype 
in 327 adult patients.12 At 48 weeks, no differences were 
found between patients achieving undetectable viral load 
in the virtual phenotype group and the genotype group 
(42% and 46%, respectively; P = 0.553).12 These discrepant 
results indicate that there are benefits and limitations to 
each type of resistance testing.13 Nevertheless, the adult 
and adolescent guidelines show preference for genotypic 
testing for treatment-naïve and pregnant patients.6
HIV life cycle and mechanism  
of drug action
In order to understand how ARVs function it is important to 
understand the HIV life cycle. The first step of viral entry is 
for HIV to locate a T lymphocyte via the CD4 receptor site.14 
After the T lymphocyte is bound, the virus must also bind to 
either a CCR5 (site of action of maraviroc) or CXCR4 core-
ceptor.15 The viral membrane then proceeds to fuse with the 
host cell membrane, via GP 41 (site of action of efuvirtide), 
enabling its RNA and proteins to enter the T lymphocyte. 
Inside the cell, viral reverse transcriptase produces HIV DNA 
using the viral RNA as a template (site of action of NRTIs 
and NNRTIs). Integrase enzyme then incorporates the HIV 
DNA into the human cell’s genome through several steps 
(site of action of integrase inhibitors). Viral DNA is then 
transcribed by human RNA polymerase, producing viral 
RNA. This RNA is translated into polyprotein precursors, 
which are then cleaved by protease into functional proteins 
(site of action of PIs).
Newer ARV treatment options  
for HIV-positive adults and children
There are several new ARV classes, as well as new agents 
from the older classes. In this study we performed an exten-
sive literature search using Medline, EMBASE, and ISI, and 
collected data regarding efficacy, safety, and   pharmacologic 
parameters of the relevant agents.
CCR5 antagonists
Maraviroc is the only currently approved CCR5 antagonist 
in clinical use. This agent acts through allosteric inhibition of 
the CCR5 receptor, preventing its interaction with gp120 and 
thus avoiding subsequent cellular entry by HIV . Data from two 
clinical trials, Maraviroc versus Optimized Therapy in Viremic 
Antiretroviral Treatment-Experienced Patients (MOTIVATE-1 
[US and Canada; n = 585] and MOTIVATE-2 [US, Australia, 
and Europe; n = 464]), have been published.16 The study inclu-
sion criteria were identical in both trials. Patients at least 16 
years of age were enrolled into the   studies if they were infected 
with a   CCR5-tropic HIV strain and were receiving at least 
one NRTI, or one NNRTI, or a fusion inhibitor, two PIs, and 
had documented resistance to at least three of the aforemen-
tioned classes.16 When administered with an optimized back-
ground therapy (OBT), more patients in the combined once-daily Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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or twice-daily maraviroc arms achieved an undetectable viral 
load (,50 copies/mL), than patients receiving placebo (43%, 
46%, and 17%, respectively, P , 0.001).16
CCR5 antagonists only work against M-tropic strains 
of HIV, which are typically found in the early stages of 
  infection.17 This is due to their exclusive use of CCR5 
coreceptors, rather than CXCR4, which is found in later 
stages of HIV .17 Therefore, maraviroc should only be used 
in patients with CCR5-tropic strains, and in not those which 
are   CXCR4-tropic, dual-tropic, or mixed-tropic.
The most common adverse events reported for maraviroc 
were diarrhea, nausea, headache, fever, fatigue, and upper respi-
ratory tract infection.16 Laboratory abnormalities were similar 
to those in the placebo arm.16 Maraviroc does carry a black box 
warning for hepatotoxicity preceded by an allergic reaction, as 
this had been reported in a healthy volunteer study.
Maraviroc has been approved by the US Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMA) for use in patients with multidrug-resistant CCR5-
tropic strains of HIV-1.18,19 A study evaluating safety, pharma-
cokinetics, and efficacy is currently enrolling children 2–18 
years of age infected with CCR5-tropic HIV-1.20 Maraviroc-
based regimens are not currently recommended for children 
younger than 16 years of age or for treatment-naïve patients.6 
It is, however, recommended for use in treatment-experienced 
adults and adolescents infected with CCR5-tropic HIV-1 
experiencing failure on their current regimen.6
Maraviroc is currently available as 150 mg and 300 mg 
tablets. A pediatric liquid formulation is currently under 
development.18–20 The monthly cost of maraviroc therapy 
is approximately $1000 USD. Because maraviroc is only 
efficacious in patients with CCR5-tropic HIV-1 strains, the 
adult and adolescent HIV-1 guidelines recommend a corecep-
tor tropism assay be performed prior to treatment initiation 
or upon failure while on maraviroc.6 The cost of the CCR5 
tropism assay (about $1960) could limit the ability to screen 
patients for the use of maraviroc.21
Fusion inhibitors
One single fusion inhibitor, enfuvirtide, is approved for 
clinical use. Enfuvirtide acts by binding to a region of the 
HIV-1 gp41 envelope protein, resulting in its inhibition, 
and thereby inhibits the steps which lead to fusion of the 
viral envelope and the cell membrane.22 Due to its unique 
mechanism of activity, enfuvirtide maintains activity against 
isolates   resistant to other ARV classes.
The efficacy of enfuvirtide was studied in two interna-
tionally conducted clinical trials of identical design, ie, the 
T-20 versus Optimized Regimen Only studies (TORO-1 [US, 
Canada, Mexico, and Brazil; n = 501] and TORO-2 [Australia 
and Europe; n = 512]).23,24 Patients 16 years of age and older 
who had previously documented ARV resistance, or who had 
received a minimum of 6 months of at least one NRTI and 
NNRTI, and at least two PIs, were eligible for participation. 
Patients were randomized to receive enfuvirtide plus an 
OBT or OBT alone. By 24 and 48 weeks, more patients in 
the enfuvirtide group achieved an undetectable viral load 
(, 50 copies/mL) than in the placebo group (15.9% versus 
6.3% and 18.3% versus 7.8%, respectively).25
The most prevalent mutations associated with enfuvirtide 
resistance result from an alteration of the active site of gp41.26 
Resistance against enfuvirtide is possible not only through muta-
tions in gp41, but also in gp120.27 The most commonly reported 
adverse events experienced by the enfuvirtide group were injec-
tion site reaction, nausea, vomiting, fatigue, headache, insomnia, 
and peripheral neuropathy.28 Pneumonia and lymphadenopathy 
occurred at significantly higher rates in the enfuvirtide group. 
Hypersensitivity   reactions can also occur.28
Enfuvirtide has been approved for use in treatment-
experienced patients 6 years of age and older infected with 
HIV-1 in both Europe and in the US.18,19 Enfuvirtide is not 
recommended for use in treatment-naïve children, but should 
be considered as an additional ARV in patients who have 
failed NRTI, NNRTI, and PI regimens.7 Because enfuvirtide 
is a synthetic peptide, and therefore cannot be administered 
orally, it is currently available as a 90 mg/mL subcutaneous 
injection. The monthly cost of enfuvirtide is $2500 USD.
Nucleoside reverse transcriptase 
inhibitors
This class consists of DNA base analogs, which are reversible 
competitive inhibitors of reverse transcriptase, effectively pre-
venting reverse transcription of viral RNA into DNA.29 There 
are currently 11 FDA-approved ARVs in this class.18 Dual 
NRTI therapy is recommended as part of therapy for treatment-
naïve patients.6 The primary mechanism of resistance to NRTIs 
involves conformational changes at the active site.30 In a recent 
study from the US and Europe, 6.1% and 3.8%, respectively, 
had NRTI resistance mutations.31 The overall incidence of 
NRTI resistance has decreased now that patients use this class 
of ARV in combination with NNRTIs and/or PIs.
Non-nucleoside reverse  
transcriptase inhibitors
NNRTIs act noncompetitively to inhibit the formation of 
DNA from viral RNA.32 Resistance to NNRTIs occurs when Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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mutations confer structural changes around the allosteric 
binding site of reverse transcriptase.33 In a study of 413 
US and 500 Western European HIV-positive ARV-naïve 
patients, 7.3% and 3.2%, respectively, had NNRTI resistance 
mutations.31
There are currently four NNRTIs approved by the FDA, 
including delavirdine, efavirenz, nevirapine, and etravirine. 
As a class, NNRTIs have a lower genetic barrier to resis-
tance than PIs, but are a line of therapy which can spare the 
use of PIs until later in life,6,7 and have much fewer drug 
  interactions, as well as gastrointestinal and lipid-related 
adverse reactions.6 Of the available agents, efavirenz is 
  recommended as first-line, with the exception of use in 
patients who are pregnant or likely to become pregnant, for 
whom nevirapine is preferred.6 For children under 3 years of 
age, nevirapine is preferred, because it is available in a liquid 
formulation.7 Efavirenz is the preferred NNRTI for use in 
HIV-infected children over the age of 3 years. Although not 
obtainable in a liquid formulation, it is available in capsules 
sized for pediatric dosing.7 As a class, the most common side 
effects of NNRTIs are rash, central nervous system effects, 
and lipoatrophy.6
Etravirine is the newest NNRTI. It is active against both 
wild-type and NNRTI-resistant HIV . Resistance is less likely 
to develop against etravirine because it is a flexible molecule 
and can bind reverse transcriptase in multiple conforma-
tions.34 Decreased response to etravirine was associated with 
the presence of three or more NNRTI mutations (Val90Ile, 
Ala98Gly, Leu100Ile, Lys101Glu, Lys101Pro, Val106Ile, 
Val179Asp, Val179Phe, Tyr181Cys, Tyr181Ile, Tyr181Val, 
Gly190Ala, and   Gly190Ser) concurrently.35
HIV-positive patients with documented resistance to 
NNRTIs, with three or more primary PI mutations and a his-
tory of having received 3 or more months of different NRTIs 
were enrolled into a Phase II etravirine clinical trial. The viral 
load had to be .1000 copies/mL. Patients were randomly 
assigned to receive either 400 mg or 800 mg of etravirine 
twice a day, or to serve as part of the control group. All patients 
on etravirine received a background regimen of at least two 
different ARVs (NRTI, lopinavir-ritonavir, or enfuvirtide). 
Patients in the control group received three or more similar 
ARVs. After 24 weeks, viral loads decreased by 1.04, 1.18, 
and 0.19 log10 copies/mL in the 400 mg, 800 mg, and control 
groups, respectively. The decrease in viral load was greater 
in the patients receiving 800 mg of etravirine and those who 
were not using either enfuvirtide or lopinavir-ritonavir. The 
percentage of patients who had viral loads ,400 copies/mL at 
24 weeks was 30% in subjects receiving 400 mg of etravirine 
and 38% in those receiving 800 mg. By comparison, only 
7.5% of subjects in the control group achieved a standard 
similar viral load.34
By 48 weeks, the viral load had decreased from baseline 
by 0.88, 1.01, and 0.14 log10 copies/mL in the etravirine 
400mg twice daily, etravirine 800 mg twice daily, and con-
trol groups, respectively. Approximately 20% of patients 
receiving either dose achieved viral loads ,50 copies/mL 
whereas none of the patients in the control group had viral 
loads ,50 copies/mL.36
The DUET-1 trial, a multicenter international trial, 
enrolled 612 patients on stable ARV therapy for at least 8 
weeks prior to screening. To be included in the study, patients 
had to have a viral load .5000 copies/mL, three or more 
primary PI mutations, and at least one mutation associated 
with NNRTI resistance. Patients were randomized to receive 
etravirine 200 mg or placebo. All patients received a suitable 
NRTI, ritonavir-boosted darunavir, and also had the option 
of receiving enfuvirtide as part of their backbone therapy. 
Primarily as a result of virologic failure, 14% of patients in the 
etravirine group and 18% of patients in the placebo group dis-
continued participation in the study prior to 24 weeks. After 
24 weeks, 56% of patients in the etravirine group and 39% in 
the placebo group had a viral load ,50 copies/mL. Of note, 
74% of subjects in the etravirine arm and 51% of patients in 
the placebo group achieved a viral load ,400 copies/mL.35
The DUET-2 trial enrolled 591 patients in Australia, 
Belgium, Canada, France, Germany, Italy, Netherlands, 
Poland, Portugal, Spain, the UK, and the US. Patients were 
randomized to the same treatment or placebo arms as in the 
DUET-1 trial. Virologic failure led to early discontinuation 
in 17% of patients on etravirine and 25% of patients on pla-
cebo. After 24 weeks, 62% of patients on etravirine and 44% 
of those on placebo had achieved a viral load ,50 copies/
mL. Additionally, 75% of patients on   etravirine achieved a 
viral load ,400 copies/mL versus 54% of patients in the 
placebo group.37
Etravirine is currently approved for use in combination 
with other ARV agents for the treatment of adults who have 
tried other treatments and have evidence of HIV-1 strains 
resistant to NNRTIs and other ARV agents.18 The monthly 
cost of etravirine is $800 USD.
The most common adverse events were diarrhea (22.0%), 
injection site reaction (related to enfuvirtide, 20.1%), fever 
(20.1%), rash (20.1%), fatigue (15.7%), headache (15.7%), 
and nausea (15.1%). Rashes appeared early in therapy, 
usually during the first 2–4 weeks, and resolved in about 
1–2 weeks with continued dosing. Rashes were mild to Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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moderate in severity and were not dose-related.36   Psychiatric 
adverse events, including mood swings, nightmares, abnor-
mal dreams, anxiety, and depression were reported in 
10.7% versus 2.5% of patients on etravirine versus placebo, 
respectively. These did not lead to any patients discontinuing 
treatment. Headache and insomnia were the most common 
adverse events related to the nervous system.34
integrase inhibitors
Currently, there is only one approved integrase inhibitor, 
raltegravir, which specifically inhibits strand transfer.38 
This step is inhibited through allosteric modification of the 
integrase enzyme, preventing its binding to host DNA.39 
Inhibition of the other steps of integration is currently in the 
preclinical research phase.
The efficacy of raltegravir was studied in two Merck 
Blocking Integrase in Treatment Experienced Patients with 
a Novel Compound against HIV , (BENCHMRK-1 [Europe, 
Asia, Australia, and Peru; n = 344] and BENCHMRK-2 
[North and South America; n = 344]) trials, which both 
used the same study design.40 They enrolled patients at least 
16 years old with HIV-1, a viral load .1000 copies/mL, 
and a documented resistance to at least one drug from each 
of the three major classes (NRTI, NNRTI, and PI). Each 
patient was randomized to an optimized background regi-
men or optimized background regimen plus raltegravir. After 
16 weeks of therapy, significantly more patients receiving the 
raltegravir-containing regimen achieved an undetectable viral 
load (less than 50 copies/mL) than in the placebo group in 
the BENCHMRK-1 trial (61.8% versus 34.7%, respectively, 
P , 0.001).40 Similar results were seen in the BENCHMRK-2 
trial.40 At 48 weeks, a combined analysis showed a signifi-
cantly higher number of patients with undetectable viral load 
(,50 copies/mL) in the raltegravir group than in the placebo 
group (62.1% versus 32.9%, respectively).40
Although the mechanism of resistance is not well under-
stood, it is known that there is no cross-resistance with other 
ARV classes. Within the class, cross-resistance with as yet 
unavailable integrase inhibitors appears to be substantial. 
Additionally, as supported by a Phase III trial, clinical failures 
were generally seen in patients who had developed a point 
mutation at one of three amino acid residues.41 Specifically, 
in one trial that enrolled patients older than 16 years showed 
that 64% of the 462 raltegravir group versus 34% of the 228 
treatment-experienced patients were counted as treatment 
failures.40
Raltegravir was generally well tolerated in the BENCH-
MRK trials, with diarrhea, nausea, headache, and fatigue 
being the most common adverse events.40 Elevated total 
cholesterol and triglyceride levels were the most common 
laboratory abnormalities reported. It is important to note that 
elevated creatine kinase levels were observed in the clinical 
trials, and that cases of myopathy and rhabdomyolysis have 
been reported since that time.40
Raltegravir has FDA and EMA approval for use in HIV-
infected adult patients.18,19 Raltegravir has also been recently rec-
ommended as a preferred regimen for treatment-naïve patients 
in the current adult and adolescent guidelines, and is considered 
a fully active ARV agent in patients naïve to integrase inhibi-
tors.6 Currently, a Phase I/II trial assessing the efficacy, safety, 
and pharmacokinetics of raltegravir is enrolling HIV-infected 
children 4 weeks to 18 years of age.42 Raltegravir is presently 
available in 400 mg tablets, with a pediatric formulation under 
investigation.18,42 The monthly cost of raltegravir is $972.00.
Protease inhibitors
There are currently 10 approved PIs, which are based on 
an analog of a peptide bond which the protease normally 
cleaves.43 This, in turn, prevents gag and gag-pol polypro-
teins from being synthesized into structural proteins and 
viral enzymes. PI-based regimens are known to confer an 
additional benefit in decreasing the development of genotypic 
mutations.44–46 By decreasing mutation rates, the likelihood 
of developing new resistance is also decreased.
Resistance to PIs generally involves a mutation affecting 
the structure of the active site of protease.47 In a recent study 
in ARV-naïve HIV-infected patients from the US and Western 
Europe, 3.6% and 0.8% of screened subjects, respectively, 
had PI resistance mutations.31
Ten PIs have been approved by the FDA, including saqui-
navir, indinavir, ritonavir, nelfinavir, amprenavir, lopinavir, 
fosamprenavir, atazanavir, darunavir, and tipranavir.6 Of 
these, ritonavir-boosted atazanvir, darunavir,   fosamprenavir, 
and lopinavir regimens are preferred, with alternative 
  regimens of ritonavir-boosted saquinavir or unboosted 
  fosamprenavir or atazanavir.6 Only ritonavir-boosted lopinavir 
is recommended as a preferred PI for children.7   Alternatively, 
ritonavir-boosted atazanavir or fosamprenavir, as well as 
unboosted nelfinavir, are recommended.7 Of these agents, 
lopinavir coformulated with ritonavir is available as a pedi-
atric oral solution and as tablets, and is approved for   children 
2 weeks of age and older.7 Fosamprenavir and nelfinavir are 
also available as pediatric suspensions, and are approved 
for use in children 2 years of age and older.7   Atazanavir is 
available in a pediatric capsule formulation, and is approved 
for use in children 6 years of age and older.7Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The PIs are generally known to produce adverse effects 
related to gastrointestinal intolerance, dyslipidemia, and 
drug metabolism.6 Of the PIs, atazanavir is known to have 
the fewest effects on lipids.6
Darunavir
Of the PIs, both darunavir and tipranavir are able to main-
tain antiviral activity against many PI-resistant HIV-1 
strains. Resistance to darunavir has been associated with 
11   mutations (V11I, V32I, L33F, I47V , I50V , I54L, I54M, 
G73S, L76V , I84V , and L89V).48 One study demonstrated 
that over 20% of treatment failures were associated with the 
V32I and I54L mutations.49 Darunavir exhibits high-affinity 
binding properties, in addition to strong chain interactions 
and potential hydrogen bonding with both the HIV-1 pro-
tease, as well as mutant proteases.50,51 This allows for greater 
activity against resistant strains as compared with other PIs. 
Furthermore, darunavir-resistant strains need to undergo 
multiple simultaneous mutations to overcome darunavir 
binding affinity.50
A darunavir-ritonavir combination is FDA-approved for 
the treatment of HIV infection in children 6 years and older 
weighing at least 20 kg.52 In adult and adolescent patients, 
darunavir–ritonavir is recommended as a preferred PI 
therapy to start in ARV-naïve patients.6 In pediatric patients, 
darunavir is recommended as a second-line treatment option 
after failure of initial therapy due to the high pill burden 
required in children weighing less than 40 kg.7 However, 
it is also suggested that darunavir may be an option for 
ARV-experienced pediatric patients.7 Currently, darunavir is 
available as 75 mg, 150 mg, 300 mg, 400 mg, and 600 mg.52 
The monthly cost of darunavir for a patient receiving 600 mg 
twice daily is $990.
The most commonly reported adverse events with 
 darunavir  include  diarrhea  (32%),  nausea  (18%), 
  nasopharyngitis (12%), headache (11%), and upper 
  respiratory tract infection (10%).53
Tipranavir
Like darunavir, tipranavir is a nonpeptidic PI, with an 
increased flexibility at the binding portion of the molecule.54 
This increased flexibility results in a greater ability to over-
come conformational changes in the protease enzyme due 
to mutations. Nonpeptidic PIs also act to prevent dimeriza-
tion of the protease, preventing its activity through multiple 
pathways.55 These advantages have been demonstrated in 
its maintenance of a relatively low IC  90 when tested against 
HIV-1 strains which had been made highly resistant to 
ritonavir.56 Interestingly, tipranavir, like other PIs, has been 
shown to modulate Pneumocystis carinii growth.57
Several predictors of response have been evaluated for tip-
ranavir. One of the earliest predictors studied was the number 
of baseline PI mutations. There are seven mutations which 
are major determinants of tipranavir resistance, ie, L33F, 
I47V , Q58E, T74P, V82L, V82T, and I84V .8 There are also 14 
mutations which play a minor role in conferring tipranavir 
resistance, ie, L10V , I13V , K20M, K20R, E35G, M36I, K43T, 
M46L, I54A, I54M, I54V , H69K, N83D, and L90M.8 It has 
been found that patients with viruses with two or fewer uni-
versal PI-associated mutations are significantly more likely to 
achieve virologic response.58,59 A derivation of counting muta-
tions is the tipranavir mutation score, whereby a genotyping 
is performed, and the mutations conferring reduced in vitro 
or in vivo tipranavir susceptibility or response are counted.60 
This measure was found to be highly variable, and had poor 
correlation with virologic response.60 Patients achieving a 
trough concentration of at least 15 µM achieved a -1.1 log10 
viral load reduction.61 In a small retrospective analysis of 
29 adult patients, tipranavir trough levels were found to be 
significantly higher in patients achieving a virologic response 
(P = 0.03).62 This, however, was not significantly associated 
with virologic response when analyzed using logistic regres-
sion (P = 0.17).63 The unbound tipranavir IC90 and IC50 are 
0.1 µM and 0.03–0.07 µM, respectively.54,64
Less traditional predictors of response have also been 
assessed. The genotypic sensitivity score, sometimes referred 
to as an optimized background score considers the number of 
drugs in the optimized background regimen which have been 
shown to be active through genotypic testing.65–67 For adult 
patients with a genotypic sensitivity score of $2, 64.2% 
achieved a virologic response, compared with a 20% virologic 
response rate for those with a score ,2.66 This trend was 
not observed in pediatric patients, possibly due to the small 
number of patients enrolled, and very few having a genotypic 
sensitivity score of $2.67 An inhibitory quotient is calculated 
by dividing the tipranavir trough by the tipranavir IC50.68–70 
A general breakpoint might be thought of as .50–60, because 
two analyses found that most patients (81%) above this level 
achieved at least a -1 log10 viral load reduction.68,69 Another 
analysis found that an inhibitory quotient of $76 had a 
response rate of 64%, whereas an inhibitory quotient ,76 
had a response rate of 29%.70
The genotypic inhibitory quotient (gIQ) is calculated by 
dividing the tipranavir serum trough concentration by the 
number of tipranavir resistance conferring mutations geno-
typed from the patient’s HIV strain.62,63,66,67,70 The measure Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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of gIQ had the highest correlation with virologic success in 
both children and adults. When correlating gIQ, tipranavir 
trough, tipranavir mutation score, use of enfuvirtide, and 
genotypic sensitivity score with virologic response in adult 
patients using logistic regression, gIQ was found to be the 
most significant predictor of virologic response (P = 0.03).63 
At 48 weeks, a significantly greater reduction in viral load 
was observed in adult patients who had a gIQ . 14,500 ng/
mL/mutation (83.3% versus 38.4%).66 At 48 weeks, pediatric 
patients with a gIQ above the first quartile (0.56–7.19) were 
more likely to achieve a viral load of ,400 copies/mL (8% 
versus 52–68%).67 A more recent assessment of gIQ found 
that patients with more than eight tipranavir resistance muta-
tions were unlikely to achieve a virologic response, regardless 
of the tipranavir trough level.62
The pharmacokinetics of a tipranavir–ritonavir combina-
tion have been studied in both adult and pediatric patients. 
Like many other PIs, tipranavir is metabolized via the 
cytochrome (CYP) p450 3A4 isozyme.71 Tipranavir should 
always be coadministered with ritonavir because of its known 
inhibition of CYP 3A4 metabolism, resulting in a boosting 
effect. This is important because tipranavir alone strongly 
induces its own metabolism, producing trough concentrations 
less than 5% of those produced by the combination.72 The 
understanding of the overall effects of the tipranavir–ritonavir 
combination on CYP p450 has been recently expanded to 
include an initial and steady-state phase.73 Upon initiating 
tipranavir–ritonavir, the ritonavir component results in strong 
inhibition of hepatic and, possibly, intestinal CYP 3A4 and 
5, along with p-glycoprotein.73 This eventually balances with 
the inductive effects of tipranavir to a moderate inhibition of 
hepatic and strong inhibition of intestinal CYP 3A4 and 5, 
with little effect on p-glycoprotein.73
Tipranavir is highly protein-bound, with .99.9% of the 
drug bound to albumin or α-1-acid glycoproteins.56 In order 
to assure adequate absorption, the capsule formulation of 
tipranavir should be administered with a high-fat meal.74 
The oral solution has been found to be unaffected by this 
dietary consideration.75
The primary adult efficacy data comes from two Random-
ized Evaluation of Strategic Intervention in multiresistant 
patients with Tipranavir (RESIST-1 [US and Australia; 
n = 620] and RESIST-2 [Europe and Latin America; n = 539]) 
trials, both of which had the same study design.76,77 Patients 
included were HIV-1 infected adults with a baseline viral load 
of at least 1000 copies/mL, at least one primary PI mutation 
corresponding to baseline PI therapy, with no more than 
two resistance-associated PI mutations. All patients were 
assessed by clinicians prior to randomization using genotypic 
testing to determine an appropriate PI, NRTI, and NNRTI 
regimen. They were then randomized to receive an unblinded 
regimen of either tipranavir boosted with ritonavir or their 
previously selected comparator PI. The primary efficacy 
endpoint measured was the proportion of patients achieving 
at least a -1 log10 viral load decrease. A higher proportion of 
patients receiving tipranavir achieved the primary endpoint 
in both the RESIST-1 (41.5% versus 22.3%; P , 0.0001) 
and RESIST-2 trials (41% versus 14.9%; P , 0.0001) at   
24 weeks.
The efficacy of tipranavir has been studied in pediatric 
patients from the US, Europe, and Latin America.78 This 
trial enrolled children 2–18 years of age who had a baseline 
viral load of more than 1500 copies/mL. Unlike the adult 
trial, treatment-naïve patients were also included and no 
resistance profile requirements were placed as criteria for 
enrollment. Children in this study were stratified by age 
into three categories, ie, 2–5, 6–11, and 12–18 years of 
age. The primary outcome for this study was safety and 
therefore it was not designed with sufficient power to 
measure efficacy outcomes. Nonetheless, viral loads as 
well as CD4 cell counts, were performed as secondary 
endpoints. As in the adult trial, patients were assigned 
an optimized background regimen prior to randomiza-
tion. Patients in this noncomparator study received an 
unblinded regimen consisting of an optimized background 
regimen, including at least two other non-PIs as well as 
either low- (290/115 mg/m2) or high-dose (375/150 mg/m2) 
tipranavir–ritonavir, with an upper dosing limit equal to 
the adult dose of 500/200 mg.
At 48 weeks, 42.6% of all patients achieved a viral load of 
,400 copies/mL. In the high-dose group, 45.6% achieved viral 
loads ,400 copies/mL compared with only 39.7% in the low-
dose group. A mean viral load decrease of 1.24 log10 copies/mL 
and 0.8 log10 copies/mL was seen in the high- and low-dose 
groups, respectively. A trend toward better efficacy was seen 
in the high-dose group with respect to viral load reduction, 
although it was not statistically   significant. As for immuno-
logic response to therapy, a median increase in CD4+ T cell 
percentages was seen in both the high- (5% increase) and 
low-dose group (3% increase), although these values were not 
statistically different (P = 0.11). The immunologic response to 
therapy was greatest in the 2–5 year age group (10% and 6% 
for the low- and high-dose groups, respectively), likely due 
to the less resistant HIV strains of the younger children. Over 
the 48-week period, four patients developed AIDS-defining 
illnesses; all four had been receiving the low-dose regimen. Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The investigators concluded that there was a potential benefit 
of the high-dose regimen over the low-dose regimen.
A total of 78 study patients were continued on or switched 
to the high-dose regimen after 48 weeks. An abstract has 
been published to summarize the long-term safety and 
efficacy data gained from these patients over 100 weeks of 
high-dose therapy.79 Overall, 38% of patients maintained 
a viral load of ,400 copies/mL and 34% maintained an 
undetectable viral load of ,50 copies/mL. The 2–5-year-old 
age group experienced the greatest virologic response, with 
56% achieving a viral load of ,400   copies/mL and 48% 
achieving an undetectable viral load of ,50 copies/mL.
Tipranavir carries a black box warning for both fatal and 
nonfatal intracranial hemorrhage, because these have been 
seen in the adult population,18 although these have not been 
observed in the pediatric or adolescent populations.78 Black 
box warnings also indicate a risk for clinical hepatitis and 
hepatic decompensation in patients with chronic hepatitis B 
or C coinfection.18 This subset of patients has been excluded 
from pediatric and adolescent tipranavir studies, and should 
apply to these populations as well. Recently, a study analyz-
ing electrocardiograms demonstrated only clinically insig-
nificant changes in corrected QT interval, with a maximum 
observation of 8.3 milliseconds for healthy patients receiving 
a supratherapeutic dose of tipranavir 750 mg.18
For the pediatric and adolescent populations, safety 
endpoints have been reported based on the Division of 
AIDS standardized toxicity grading table.80 The 48-week 
safety outcomes were not out of the ordinary, with 53.9% of 
patients experiencing a drug-related adverse event, 25.2% 
of patients experiencing a serious adverse event, and 8.7% 
patients   discontinuing use of the study drug due to an adverse 
event.78 The most commonly reported adverse events were 
nausea, vomiting, diarrhea, and headache. An increased risk 
of bleeding was also described in the pediatric and adolescent 
study.78 When considering laboratory abnormalities, eleva-
tions in gamma-glutamyl transpeptidase and alanine transami-
nase led to discontinuation of tipranavir in four patients.78
A subanalysis from the RESIST trials assessed 
health-related quality of life in patients receiving tipranavir-
containing regimens versus those receiving a comparator 
protease.81 It was found that changes in health-related quality 
of life from baseline were similar between groups.
Currently, tipranavir in combination with ritonavir is 
FDA-approved for use in patients 2 years of age and older, 
who are treatment-experienced and infected with an HIV-1 
strain clinically resistant to more than one PI.18 The European 
Medicines Agency has given a positive opinion for tipranavir 
use in highly pretreated adolescents (.12 years old) with 
evidence of resistance to multiple PIs, and also in highly 
pretreated children aged 2–12 years. The tipranavir–ritonavir 
combination is not currently   recommended as initial therapy 
according to the adult and adolescent guidelines.6
Conclusions
The tipranavir–ritonavir combination provides another 
promising line of therapy for patients infected with viruses 
exhibiting PI resistance. Tipranavir has been proven to be 
relatively safe in both the adult and pediatric populations, 
giving a valuable alternative for these patients. The PI class 
effect in decreasing the formation of new mutations makes 
tipranavir agent more desirable for HIV strains already highly 
resistant to other ARV therapies.
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